Company news
Claritas Pharmaceuticals Inc. (OTC:CLAZF) news
Claritas Pharmaceuticals Inc. news releases on 6ix. Latest, Apr 7, 2022: Claritas Announces Approval from OTC to Up-List to OTCQB
Press releases & updates
Claritas Announces Approval from OTC to Up-List to OTCQB
April 7, 2022
Claritas Announces Approval from Australian Ethics Committee to Begin Phase 1 Trial of R-107
April 5, 2022
BCSC-OSC Revocation of Cease Trade Order
January 21, 2021
BCSC-OSC Partial Revocation of Cease Trade Order
July 13, 2020
BCSC Cease Trade Order
June 21, 2020
Kalytera Announces Binding Agreement to Acquire Salzman Group
May 19, 2020
Kalytera Announces Updates to Its Annual and Interim Filings
April 28, 2020
Kalytera and Stero Biotechs Will Not Proceed with Acquisition
April 13, 2020
Kalytera Provides Additional Detail Regarding Terms of Stero Biotechs, Ltd. Acquisition
March 18, 2020
Kalytera Announces Extension of Maturity Date of Promissory Note
March 16, 2020
Kalytera Announces Trading Halt
March 5, 2020
Kalytera to Acquire Stero Biotechs, Ltd.
March 5, 2020
Kalytera Announces Modification to Sale Period for Shares Issued under Payments Agreement
February 18, 2020
Kalytera Completes Share Issuance under Payments Agreement
February 19, 2020
Kalytera Announces New Payments Agreement with the Salzman Group of Israel
February 7, 2020
Kalytera Announces Notice of Allowance of Additional U.S. Patent for Prevention and Treatment of Graft Versus Host Disease
February 5, 2020
Kalytera Announces Intention to Seek Amendment of Secured Convertible Debentures Due December 2019
December 20, 2019
Kalytera Announces Extension of Maturity Date of Promissory Note
December 16, 2019
Kalytera Reports Third Quarter 2019 Financial Results
December 2, 2019
Published Studies Provide Further Support For Kalytera’s Program Evaluating CBD in GVHD
November 22, 2019
Kalytera Announces Closing of Final Tranche of Private Placement of Common Shares and Common Share Purchase Warrants and Amendments to Secured Convertible Debenture Units
October 30, 2019
Kalytera Provides Update on Private Placement of Common Shares and Common Share Purchase Warrants
October 21, 2019
Kalytera Terminates Plan to Acquire CBD Extraction Facility
October 17, 2019
Kalytera Announces Notice of Allowance of EU Patent for Prevention and Treatment of Graft Versus Host Disease
October 2, 2019
Kalytera Announces Closing of First Tranche of Private Placement of Common Shares and Common Share Purchase Warrants
September 16, 2019
Kalytera Announces Update to Private Placement
September 11, 2019
Kalytera Announces Interest Payment in Shares
September 9, 2019
Kalytera Reports Second Quarter 2019 Financial Results
August 29, 2019
Kalytera Announces Management-Led Private Placement of Up To $1.5 Million of Common Shares and Common Share Purchase Warrants
August 21, 2019
Kalytera to Conclude Phase 2 Clinical Study and Initiate Phase 3 Study
August 20, 2019
Kalytera Announces Results of Shareholder Meeting Votes
July 29, 2019
Kalytera Will Not Proceed with Vote on Potential Share Consolidation
July 26, 2019
Kalytera Announces Completion of Food Effect and QTc Study
July 16, 2019
Kalytera to Hold Annual and Special Meeting on July 29, 2019
July 5, 2019
Kalytera to Acquire CBD Extraction Business
June 27, 2019
Kalytera Provides Update on GVHD Program
June 25, 2019
Kalytera Announces Grant of Stock Options to Directors
June 21, 2019
Kalytera Announces Changes to Board of Directors
June 21, 2019
Kalytera Announces Additional Progress with Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain
June 18, 2019
Kalytera Reports First Quarter 2019 Financial Results
May 31, 2019
Kalytera Announces Submission of Patent Application to the U.S. Patent and Trademark Office
May 29, 2019
Kalytera Announces Data Further Elucidating CBD’s Mechanisms of Action in Prevention of GVHD
May 28, 2019
Kalytera Announces Engagement of Echelon Wealth Partners to Assist with Review of Potential Out-License Opportunities for Commercial Rights to GVHD Products
May 21, 2019
Kalytera Therapeutics, Inc. Announces Second Closing of Public Offering
May 14, 2019
Kalytera Reports 2018 Financial Results
May 1, 2019
Kalytera Therapeutics, Inc. Announces Closing of Public Offering
April 26, 2019
Kalytera Therapeutics Announces Filing of Short Form Prospectus
April 17, 2019
Kalytera Therapeutics Announces Short Form Prospectus Offering of Units
April 3, 2019
Kalytera Reports Data for First Cohort in Phase 2 Clinical Study Evaluating CBD in Prevention of Acute GVHD
March 22, 2019
Kalytera Announces Closing of Private Placement of Convertible Debenture Units
March 7, 2019